Limited Coverage Drugs - pioglitazone
Generic Name |
pioglitazone |
---|---|
Strength |
|
Form |
tablet |
Special Authority Criteria |
Approval Period |
---|---|
To be administered as part of a combination treatment for type 2 diabetes mellitus:
Notes:
|
Indefinite |
Practitioner Exemptions
- None
Special Notes
- PharmaCare coverage for pioglitazone is intended for combination treatment of type 2 diabetes (e.g., not as monotherapy).
- Patients intolerant to a sulfonylurea may be considered for coverage. Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the PharmaCare Special Authority program).
- Clinical judgment is warranted to assess the increased risk of adverse outcomes in patients with concurrent cardiovascular conditions, including heart failure.
Special Authority Request Form(s)